Phase 2 Study To Evaluate Safety And Efficacy Of Investigational Drug - PF04937319 In Patients With Type 2 Diabetes

• Status: Completed
• Trial end date: 2013-01-01
• Target enrollment: 0
• Participant gender: All

Summary

B1621007 is designed to study the safety and efficacy of PF-04937319 in patients with type 2 diabetes

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Sitagliptin Phosphate

Criteria

Inclusion Criteria:

• patients with type 2 diabetes, on metformin, age between 18-55 yrs, male or female

Exclusion Criteria:

• patients with type 1 diabetes, medically unstable, unacceptable clinical laboratory test results at screening